Johnson & Johnson’s acquisition of Shockwave Medical for approximately $13.1 billion marks a major milestone in the company’s medtech strategy, reinforcing its leadership in cardiovascular treatment and long-term growth. The deal brings Shockwave’s intravascular lithotripsy IVL technology into Johnson & Johnson MedTech’s portfolio, strengthening its ability to treat calcified coronary artery disease CAD and peripheral artery disease PAD, two of the most complex areas in cardiac intervention.
Expanding Leadership in Cardiovascular Innovation:
Cardiovascular disease remains one of the leading causes of death worldwide, creating a strong need for advanced and minimally invasive treatment solutions. By integrating IVL technology, Johnson & Johnson enhances its interventional cardiology portfolio with a differentiated solution that uses sonic pressure waves to break up calcified plaque and restore blood flow. This strategic step deepens the company’s presence in high growth cardiovascular segments while complementing its existing medical cardiovascular device capabilities.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, emphasized that addressing cardiovascular disease is central to the company’s mission. He stated that Shockwave’s leading technology strengthens Johnson & Johnson’s ability to deliver value to patients, physicians, and health systems while driving sustainable shareholder returns.
Executive Perspective on Innovation and Growth:
Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, described Shockwave as a highly differentiated platform that enhances the company’s leadership in medical technology. He highlighted that IVL expands Johnson & Johnson’s reach in complex coronary and peripheral interventions and provides access to a strong innovation pipeline designed to improve patient outcomes globally.
Doug Godshall, President and CEO of Shockwave Medical, noted that IVL has transformed the treatment of calcified arterial disease. He expressed confidence that joining Johnson & Johnson will accelerate global adoption of the technology, helping establish IVL as a standard of care while expanding access to life changing therapies.
Supporting the Company’s Long-Term Vision:
Following the spin-off of its consumer health business, Johnson & Johnson has sharpened its focus on Innovative Medicine and MedTech. The acquisition of Shockwave aligns with this transformation by strengthening its portfolio in high impact and high growth healthcare segments. By combining Shockwave’s innovation with Johnson & Johnson’s global scale, research capabilities, and distribution network, the company is positioning itself for continued leadership in advanced cardiovascular solutions.
The integration also supports the broader vision of delivering science driven innovation that addresses unmet medical needs. With rising demand for minimally invasive procedures and advanced interventional therapies, the company is strategically aligning its investments to capture future growth opportunities.
Future Growth Outlook in Cardiovascular Care:
Shockwave’s IVL platform is expected to contribute meaningfully to Johnson & Johnson MedTech’s revenue growth over the coming years. The company plans to leverage its commercial infrastructure to expand IVL adoption across new geographies and clinical settings. Continued research and development investments are likely to drive next generation advancements in catheter-based technologies and complementary cardiovascular solutions.
This acquisition strengthens Johnson & Johnson’s competitive positioning in a market characterized by rapid technological evolution and increasing procedural demand. By focusing on innovation, clinical excellence, and global accessibility, the company is building a future ready cardiovascular franchise.
Conclusion:
Johnson & Johnson’s acquisition of Shockwave Medical represents a powerful step forward in its mission to transform cardiovascular care. Through the integration of breakthrough IVL technology, the company reinforces its commitment to innovation, patient outcomes, and long-term growth. Executive insights from both organizations reflect a shared vision of expanding access to advanced therapies and setting new standards in interventional cardiology. As healthcare continues to evolve, Johnson & Johnson is positioning itself at the forefront of cardiovascular innovation, ensuring sustainable growth while delivering meaningful impact for patients worldwide.
Source - Johnson & Johnson
